Skip to content

Study · Randomized controlled trial · 2022

3 results

Pharmacokinetics and Pharmacodynamics of Repository Corticotropin Injection Compared With Synthetic ACTH1-24 Depot and Methylprednisolone in Healthy Subjects.

Poola N, Due B, Wright D, Brooks LR, Zaman F

Clinical pharmacology in drug development15 Sept 2021Cited by 15 (Europe PMC)

PMID34528408 (opens in a new tab)PMCIDPMC9290342 (opens in a new tab)DOI10.1002/cpdd.1020 (opens in a new tab)PepBankPUB-34528408
Read at sourcePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialMechanism

    In healthy adults, Acthar induced about 5-fold lower free cortisol exposure than synthetic ACTH1-24 depot after 2 doses.

    In plain wordsIn healthy adults, Acthar produced about 5-fold lower free cortisol exposure than synthetic ACTH1-24 depot.

    Peptide
    ACTH (corticotropin)
    Outcome
    DecreaseFree cortisol exposure
    Study

    n: not reported in source

    Comparator
    Synthetic ACTH1-24 depot
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    80 IU twice weekly on study days 1 and 4 · subcutaneousAs given in this study (human).

    Measurements

    Free cortisol exposure
    ≈ 5 fold lower
    RCI versus synthetic ACTH1-24 depot after 2 doses

    Source sentences

    Summary
    After 2 doses, RCI induced about 5-fold lower free cortisol exposure and an estimated 4-fold lower steroidogenic exposure than synthetic ACTH1-24 depot.
    2 context sentences
    Summary · context
    This phase 1, single-center, open-label, randomized parallel study directly compared the pharmacokinetics and pharmacodynamics of RCI and synthetic ACTH1-24 depot.
    Summary · context
    A total of 48 healthy subjects aged 18 to 50 years were randomly assigned 1:1:1 to RCI (80 IU subcutaneously twice weekly on study days 1 and 4)
  2. 02HumanRandomized controlled trialMechanism

    In healthy adults, Acthar induced an estimated 4-fold lower steroidogenic exposure than synthetic ACTH1-24 depot after 2 doses.

    In plain wordsIn healthy adults, Acthar produced an estimated 4-fold lower steroidogenic exposure than synthetic ACTH1-24 depot.

    Peptide
    ACTH (corticotropin)
    Outcome
    DecreaseEstimated steroidogenic exposure
    Study

    n: not reported in source

    Comparator
    Synthetic ACTH1-24 depot
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    80 IU twice weekly on study days 1 and 4 · subcutaneousAs given in this study (human).

    Measurements

    Steroidogenic exposure
    ≈ 4 fold lower
    RCI versus synthetic ACTH1-24 depot after 2 doses, estimated

    Source sentences

    Summary
    After 2 doses, RCI induced about 5-fold lower free cortisol exposure and an estimated 4-fold lower steroidogenic exposure than synthetic ACTH1-24 depot.
    2 context sentences
    Summary · context
    This phase 1, single-center, open-label, randomized parallel study directly compared the pharmacokinetics and pharmacodynamics of RCI and synthetic ACTH1-24 depot.
    Summary · context
    A total of 48 healthy subjects aged 18 to 50 years were randomly assigned 1:1:1 to RCI (80 IU subcutaneously twice weekly on study days 1 and 4)
  3. 03HumanRandomized controlled trialPharmacokinetics

    In healthy adults, Acthar's N25-deamidated porcine ACTH marker had higher mean plasma concentrations than ACTH1-24 after the comparator depot.

    In plain wordsIn healthy adults, Acthar's porcine ACTH marker reached higher mean plasma concentrations than ACTH1-24 after the comparator depot.

    Peptide
    ACTH (corticotropin)
    Outcome
    IncreaseMean plasma pharmacokinetic marker concentration
    Study

    n: not reported in source

    Comparator
    Synthetic ACTH1-24 depot
    Outcome group
    Pharmacokinetics · Endocrine and hormones
    Studied dose
    80 IU twice weekly on study days 1 and 4 · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    The lower endogenous cortisol response of RCI was achieved despite higher observed mean plasma concentrations of N25-deamidated porcine ACTH1-39 (the pharmacokinetic marker for RCI) than of ACTH1-24 .
    2 context sentences
    Summary · context
    This phase 1, single-center, open-label, randomized parallel study directly compared the pharmacokinetics and pharmacodynamics of RCI and synthetic ACTH1-24 depot.
    Summary · context
    A total of 48 healthy subjects aged 18 to 50 years were randomly assigned 1:1:1 to RCI (80 IU subcutaneously twice weekly on study days 1 and 4)

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.